SPOTLIGHT -
Irvine, CA-IntraLase Corp. glided into the public realm in early October with a successful initial public offering (IPO) at the top of its indicated range, selling nearly 7.3 million shares and raising $86.6 million.
Bausch + Lomb announces results from a clinical study of a novel daily nutritional supplement for dry eyes
(EyePod) From idea to impact: Navigating ophthalmic innovation
The Fred Hollows Foundation supporting 2030 IN SIGHT LIVE
EyePod: Modifier Gene Therapy: What is it?
Verana Health launches its Qdata Thyroid Eye Disease module
Gene editing untangles one strand of the AMD web